0000000000433799

AUTHOR

Giovanni Rosti

showing 3 related works from this author

Differences among young adults, adults and elderly chronic myeloid leukemia patients

2014

Abstract BACKGROUND: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. PATIENTS AND METHODS: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CML WP over a 40-year period. RESULTS: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old)…

MalePediatricsHost responseBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Oncology; HematologyTyrosine kinase inhibitorDiseaseAntineoplastic AgentTyrosin kinase inhibitorProtein-Tyrosine Kinasehemic and lymphatic diseases80 and overAge FactorProspective StudiesYoung adultChronicBCR-ABLAged 80 and overLeukemiaIncidence (epidemiology)Chronic myeloid leukemiaAge FactorsMyeloid leukemiaHematologyMiddle AgedProtein-Tyrosine KinasesPrognosisLeukemiaOncologybcr-abl1FemaleBCR-ABL; chronic myeloid leukemia; prognosis; tyrosine kinase inhibitors; young adultsHumanAdultyoung adultsmedicine.medical_specialtyPrognosiProtein Kinase InhibitorAntineoplastic Agentschronic myeloid leukemia; bcr-abl1; Tyrosin kinase inhibitor; prognosis; young adultsNOYoung Adultchronic myeloid leukemiaLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young AdultProtein Kinase InhibitorsAgedTyrosine kinase inhibitorsAdult patientsbusiness.industrymedicine.diseaseClinical trialBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Hematology; OncologyProspective StudieBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Medicine (all); Hematology; OncologyImmunologySplenomegalyBCR-ABL PositiveBCR-ABL chronic myeloid leukemia prognosis tyrosine kinase inhibitors young adultsprognosisbusinessSpleenYoung adultsMyelogenous
researchProduct

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consens…

2008

Objectives: The first consensus report presented by the European Germ Cell Cancer Consensus Group (EGCCCG) in the year 2004 has found widespread approval by many colleagues throughout the world. In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, Amsterdam, The Netherlands. Methods: Medical oncologists, urological surgeons, radiation oncologists as well as pathologists from several European countries reviewed and discussed the data that had emerged since the 2002 conference, and incorporated the new data into updated and revised guidelines. As for the first meeting, the methodology of evidence-based medicine (EBM) wa…

MaleMESH: Combined Modality TherapyBiopsyConsensus Development Conferences as Topic030232 urology & nephrologyMembrane transport and intracellular motility [NCMLS 5]MESH: Biopsy0302 clinical medicineStage I SeminomaMESH: Practice Guidelines as TopicMedicineSocieties MedicalMESH: Testicular NeoplasmsConsensus conferenceMESH: Neoplasm StagingNeoplasms Germ Cell and EmbryonalPrognosisPrimary tumorCombined Modality Therapy3. Good healthEurope030220 oncology & carcinogenesisPractice Guidelines as TopicMESH: Neoplasms Germ Cell and Embryonalmedicine.medical_specialty[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]ConsensusUrologyMESH: Societies MedicalMEDLINEMESH: Prognosis03 medical and health sciencesSDG 3 - Good Health and Well-beingTesticular NeoplasmsInterventional oncology [UMCN 1.5]HumansMESH: ConsensusTesticular cancerNeoplasm StagingGynecologyMESH: Humansbusiness.industryMESH: Consensus Development Conferences as Topicmedicine.diseaseMESH: MaleClinical trialGerm cell cancerFamily medicineGerm cell tumorsMESH: EuropebusinessEuropean Urology
researchProduct

Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.

2003

The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy. The median age of the patients was 57 years (range 22-67). In all, 268 patients received peripheral blood stem cells, and 47 patients received autologous bone marrow. After a median follow-up of 57 months (range 10-125), three cases of secondary AML (sAML) were observed, resulting in a cumulative incidence of 0.94%. One case of sAML developed 18 months after HDCT (FAB M3) The karyotype was trans…

OncologyTransplantation Conditioningmedicine.medical_treatmentAutologous stem-cell transplantationLeukemia Promyelocytic Acutehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMelphalanBone Marrow TransplantationLeukemia Radiation-InducedAcute leukemiaIncidenceCytarabineNeoplasms Second PrimaryHematologyMiddle AgedCombined Modality TherapyLeukemia MyeloidLymphatic MetastasisAcute DiseaseFemalemedicine.drugAdultmedicine.medical_specialtyPaclitaxelBreast NeoplasmsTransplantation AutologousLeukemia Myelomonocytic AcuteBreast cancerInternal medicinemedicineAdjuvant therapyHumansCyclophosphamideAgedEpirubicinTransplantationChemotherapyMitoxantronePeripheral Blood Stem Cell Transplantationbusiness.industryDaunorubicinmedicine.diseaseSurgeryRadiation therapyTransplantationDoxorubicinRadiotherapy AdjuvantMitoxantronebusinessThiotepaBone marrow transplantation
researchProduct